Blog

Five Key Trends in ABAC Enforcement Demand A Strategic Response From Companies

In the rapidly evolving anti-bribery and anti-corruption (ABAC) enforcement environment, boards and senior managers need a strategic approach to tackling this issue more than ever before. The volume of enforcement activity continues to be high. Investigations and prosecutions in the US remain robust in spite of initial concerns about the impact of Trump administration policies, and global monetary sanctions imposed by the world’s regulators on entity groups in US Foreign Corrupt Practices Act (FCPA)-related investigations totaled $3.2 billion in 2018, the second highest total over the past decade.

Read More

Topics: FCPA, Anti-Bribery and Anti-Corruption, SEC, DOJ, uk sfo, sanctions, US Department of Justice, ABAC enforcement, ABAC compliance, World Bank

Speaking of Risk: Pharmaceutical Companies and Third Party Promotions

Pharmaceutical companies around the world are struggling to keep up with the rapid evolution of ethical frameworks around bribery and corruption in their industry.
Read More

Topics: Pharma, Anti-bribery & Anti-corruption, FCPA, Medical Companies, SEC, Corruption, Bribery, DOJ, teva, Pharmaceutical Companies, settlement, fines, gsk

The DOJ’s “Evaluation of Corporate Compliance Programs”

Guidance for your FCPA Programs

On the 8th of February the Fraud Section of the DOJ released fresh guidance in the form of its “Evaluation of Corporate Compliance Programs,” which provides a list of questions that prosecutors will typically ask about a compliance program.

Read More

Topics: FCPA, risk and compliance, Third Party Management, Global 2000, DOJ, KYTP